ArticleEClinicalMedicine2025

Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial.

Yu-Chen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.